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Tumor maintenance relies on continued activity of
driver oncogenes, although their rate-limiting role is
highly context dependent. Oncogenic Kras mutation
is the signature event in pancreatic ductal adenocar-
cinoma (PDAC), serving a critical role in tumor
initiation. Here, an inducible KrasG12D-driven PDAC
mouse model establishes that advanced PDAC
remains strictly dependent on KrasG12D expression.
Transcriptome and metabolomic analyses indicate
that KrasG12D serves a vital role in controlling tumor
metabolism through stimulation of glucose uptake
and channeling of glucose intermediates into the
hexosamine biosynthesis and pentose phosphate
pathways (PPP). These studies also reveal that onco-
genic Kras promotes ribose biogenesis. Unlike
canonical models, we demonstrate that KrasG12D
drives glycolysis intermediates into the nonoxidative
PPP, thereby decoupling ribose biogenesis from
NADP/NADPH-mediated redox control. Together,656 Cell 149, 656–670, April 27, 2012 ª2012 Elsevier Inc.this work provides in vivo mechanistic insights into
how oncogenic Kras promotes metabolic reprog-
ramming in native tumors and illuminates potential
metabolic targets that can be exploited for thera-
peutic benefit in PDAC.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is among the most
lethal cancers with a 5-year survival rate of 5% (Hidalgo,
2010). Malignant progression from pancreatic intraepithelial
neoplasia (PanINs) to invasive and metastatic disease is accom-
panied by the early acquisition of activating mutations in the
KRAS oncogene, which occurs in >90% of cases, and subse-
quent loss of tumor suppressors including INK4A/ARF, TP53,
and SMAD4 (Hezel et al., 2006). Genetically engineered mouse
models (GEMM) have provided evidence for oncogenic Kras
(KrasG12D) as amajor driver in PDAC initiation, with the aforemen-
tioned tumor suppressor genesconstrainingprogression (Aguirre
et al., 2003; Guerra et al., 2003; Hingorani et al., 2003). Although
shRNA extinction of Kras expression as well as pharmacological
inhibition of its effectors can impair growth of human PDAC lines,
clinical trials of drugs targeting key components of the RAS-
MAPK pathway have shown meager responses (Rinehart et al.,
2004; Singh and Settleman, 2009). The paucity of clinical prog-
ressmay relate toanumberof factors including the lackof a tumor
maintenance role for oncogenicKras, redundancy indownstream
signaling surrogates, suboptimal penetration of the drug into the
tumor, and/or tumor plasticity owing to amyriad of genomic alter-
ations and intratumoral heterogeneity (Hidalgo, 2010).
Constitutive KrasG12D signaling drives uncontrolled prolifera-
tion and enhances survival of cancer cells through the activation
of its downstream signaling pathways, such as the MAPK and
PI3K-mTORpathways (Gysin et al., 2011). Tomeet the increased
anabolic needs of enhanced proliferation, cancer cells require
both sufficient energy and biosynthetic precursors as cellular
building blocks to fuel cell growth. In cancer cells, metabolic
pathways are rewired in order to divert nutrients, such as glucose
and glutamine, into anabolic pathways to satisfy the demand for
cellular building blocks (Vander Heiden et al., 2009). Accumu-
lating evidence indicates that the reprogramming of tumor
metabolism is under the control of various oncogenic signals
(Levine and Puzio-Kuter, 2010). The Ras oncogene in particular
has been shown to promote glycolysis (Racker et al., 1985;
Yun et al., 2009). However, the mechanisms by which oncogenic
Kras coordinates the shift in metabolism to sustain tumor
growth, particularly in the tumor microenvironment, and whether
specific metabolic pathways are essential for Kras-mediated
tumor maintenance remain areas of active investigation. Here,
we generated an inducible oncogenic Kras model of PDAC
and establish that this gene is essential for tumor maintenance
in vivo. Integrated transcriptomic, biochemical, and metabolo-
mic analyses reveal a fundamental role of the Kras oncogene
in reprogramming tumor metabolism by selectively activating
biosynthetic pathways to maintain tumor growth.
RESULTS
KrasG12D Is Essential for PDAC Maintenance
To control KrasG12D expression in a temporal- and tissue-
specific manner, we generated a conditional KrasG12D transgene
under the control of a tet-operator with a lox-stop-lox (LSL)
cassette inserted between the promoter and the start codon of
the KrasG12D open reading frame (tetO_Lox-Stop-Lox-KrasG12D,
designated tetO_LKrasG12D) (Figure S1A available online).
These mice were crossed to ROSA26-LSL-rtTA-IRES-GFP
(ROSA_rtTA) (Belteki et al., 2005) and p48-Cre (Kawaguchi
et al., 2002) mice to enable pancreas-specific and doxycycline
(doxy)-inducible expression of KrasG12D (Figure S1B). This triple
transgenic strain is designated hereafter as iKras. Doxy treat-
ment effectively induced oncogenic Kras expression and activity
(Figures S1C and S1D), but did not substantially increase total
Kras expression at the mRNA or protein levels (Figures S1C
and S1E). Extinction of the KrasG12D transgene occurs within
24 hr following doxy withdrawal (Figures S1C and S1D).
Consistent with the role of KrasG12D as a driver of PDAC initi-
ation (Hezel et al., 2006), doxy induction provokes acinar-to-
ductal metaplasia and PanIN lesions within 2weeks (Figure S1F).
Similar to the LSL-KrasG12D knock-in model, induction of the
KrasG12D transgene leads to infrequent occurrence of invasivePDAC after long latency (35–70 weeks) (Figure S1F), suggesting
comparable biological activity of the KrasG12D alleles and the
need for additional genetic events for tumor progression. To
enable full malignant progression and assess the tumor mainte-
nance role of KrasG12D in advanced malignancies, we crossed
iKras and conditional p53 knockout (p53L) alleles (Marino et al.,
2000). Following doxy treatment at 3 weeks of age, all iKras
p53L/+ mice succumbed to PDAC between 11 and 25 weeks of
age (median survival, 15 weeks), whereas the doxy-treated iKras
p53L/L mice succumbed to PDAC more rapidly with a median
survival of 7.9 weeks (Figure 1A). The iKras p53 mutant tumors
exhibited features commonly found in human PDAC, including
glandular tumor structures, exuberant stroma, local invasion
into surrounding structures such as the duodenum, and distant
metastases to the liver and lung (Figure 1B). Histological analysis
documented invasive PDAC in 8/8 iKras p53L/+ mice at 8 weeks
after induction (Figure S1G). As such, we assessed the impact of
KrasG12D extinction on tumor biology and maintenance at
9 weeks after induction. As shown in Figure 1C, KrasG12D extinc-
tion led to rapid tumor regression with morphological deteriora-
tion of tumor cells and rapid degeneration of stromal elements
starting 48 hr and peaking at 72 hr following doxy withdrawal.
After 1 week of doxy withdrawal, MRI showed a reduction in
tumor mass of 50%, whereas PET/CT showed complete loss
of fluorodeoxyglucose (FDG) uptake (Figures 1D and 1E). On
the histopathological level, virtually all malignant components
of the tumor regressed with the remaining pancreata displaying
collagen deposition surrounding few remnant ductal structures
(Figure 1C). Correspondingly, tumor regression was accompa-
nied by decreased tumor cell proliferation (BrdU incorporation)
and increased apoptosis (Caspase-3 activation) 2–3 days after
doxy withdrawal, culminating in complete loss of tumor cell
proliferation at 1 week off doxy (Figures 2A and S2A; data
not shown). Moreover, KrasG12D extinction effected dramatic
changes in the tumor stroma as evidenced by a reduction in
pancreatic stellate cells (marked by SMA staining) (Figure 2A),
which is a prominent component of the classical stromal reaction
in PDAC. This indicates that oncogenic Kras has significant non-
cell-autonomous effects on the stromal compartment. The in vivo
findings of decreased proliferation and increased apoptosis of
the epithelial compartment parallel cell culture assays, such as
loss of clonogenic growth of primary tumor cells (Figure S2B),
consistent with a role for cell-autonomous mechanisms contrib-
uting to tumor regression. Together, these findings establish that
KrasG12D expression is required for PDAC maintenance in this
autochthonous model, supporting both the proliferation and
viability of tumor cells and its associated stroma.
These biological changes aligned with changes in prototypical
Kras signaling components, including a decrease in MAPK
signaling measured by phospho-Erk as early as 24 hr following
doxy withdrawal (Figure 2B), preceding any obvious changes
in tumor morphology. Decreased phospho-Erk was followed
by dampened mTOR signaling, as evidenced by a decreased
phospho-S6 in tumor cells, although the signal remained high
in some stromal cells (Figure 2B). These in vivo signaling patterns
matched those seen in cultured tumor cells (Figure S2C). As ex-
pected, LSL-KrasG12D p53L/+ primary tumor cell cultures showed
no doxy-dependent signaling changes (Figure S2D).Cell 149, 656–670, April 27, 2012 ª2012 Elsevier Inc. 657
Figure 1. KrasG12D Inactivation Leads to Rapid Tumor Regression
(A) Kaplan-Meier overall survival analysis for mice of indicated genotypes. Cohort size for each genotype is indicated. Arrow: time point for starting doxy
treatment. On: mice were fed with doxy-containing water from 3 weeks of age. Off: mice were maintained doxy-free.
(B) Histopathological characterization of PDAC from iKras p53L/+ mice showing (i) typical ductal adenocarcinoma with well-differentiated glandular tumor cells
and strong stromal reaction; (ii) local invasion of tumor cells (right of the dotted line) into duodenum wall; (iii) liver metastasis (arrow); and (iv) lung metastasis
(arrow).
(C) H&E staining shows histological changes of PDAC at the indicated time points after doxy withdrawal. Scale bar represents 100 mm.
(D) MRI scan illustrating tumor (area within the dotted line) shrinkage following 7 days of doxy withdrawal.
(E) 18FDG-PET/CT scan of tumor bearing mice at day 0 and day 7 upon doxy withdrawal. *, tumor; Kd, kidney; Bd, bladder dome.
See also Figure S1.KrasG12D Regulates Multiple Metabolic Pathways at the
Transcriptional Level
To gain further mechanistic insight into KrasG12D-mediated
tumor maintenance, transcriptomic analysis was conducted
using orthotopic iKras p53 null tumors generated from five inde-
pendent primary tumor lines. Importantly, these orthotopic658 Cell 149, 656–670, April 27, 2012 ª2012 Elsevier Inc.tumors faithfully recapitulated histological and molecular
features of the primary tumors (Figure S3A). To audit proximal
molecular changes linked to KrasG12D extinction, tumors were
harvested at 24 hr following doxy withdrawal. This time point
shows documented loss of Ras activity (Figure 3A), yet absence
of morphological changes or a significant decrease in
Figure 2. Histopathological Characterization of
Tumor Regression upon KrasG12D Inactivation
(A) iKras p53L/+ mice were fed with doxy-containing water
for 9 weeks from 3 weeks of age. The mice were pulled
from doxy treatment at the indicated days and injected
with BrdU. Pancreatic tumors were stained with anti-
bodies to BrdU (panels i, iv, vii, x), cleaved-caspase3
(panels ii, v, viii, xi), and SMA (panels iii, vi, ix, xii).
(B) Pancreatic tumors from (A) were stained with anti-
bodies to phospho-Erk (panels i, iii, v, vii) and phospho-S6
(panels ii, iv, vi, viii). Scale bar represents 100 mm.
See also Figure S2.proliferation (Figure S2A). Gene set enrichment analysis (GSEA)
(Subramanian et al., 2005) of the in vivo and in vitro KrasG12D
transcriptome using the KEGG gene sets showed striking repre-
sentation of metabolic processes, including the downregulation
of steroid biosynthesis, pyrimidine metabolism, O-glycan
biosynthesis, and glycan structures biosynthesis pathways
(Figures 3B and 3C and Table S1). Moreover, xenograft tumors
and cultured parental lines exhibited significant correlation in
expression levels for the differentially expressed genes (Fig-
ure S3B), suggesting that the cultured tumor cell lines may serve
to complement tumor studies in vivo.
KrasG12D Enhances Glycolytic Flux
To interrogate the role of KrasG12D in the regulation of tumor
metabolism, targeted liquid chromatography-tandem mass
spectrometry (LC-MS/MS) metabolomic studies were per-
formed to comprehensively characterize metabolic alterations
immediately following KrasG12D withdrawal (Yuan et al., 2012).
This analysis revealed that KrasG12D extinction effected signifi-
cant metabolic changes involving multiple pathways, the most
significant of which are intermediates in glucose metabolism
(Figures 4A and 4B). Consistent with the function of KrasG12D
in the regulation of glycolysis (Racker et al., 1985), KrasG12D
extinction was accompanied by a significant drop in glucose-
6-phosphate (G6P), fructose-6-phosphate (F6P), and fructose-
1,6-bisphosphate (FBP) with minimal changes to the remaining
components in glycolysis (Figure 4E). In addition, KrasG12D
extinction led to decreased glucose uptake and lactate produc-Cell 149tion (Figures 4C and 4D), demonstrating that
oncogenic KrasG12D enhances glycolytic flux in
PDAC. These metabolic changes were highly
concordant with the gene expression changes
from the transcriptional profiles, which showed
downregulation of the glucose transporter
(Glut1/Slc2a1) and several other rate-limiting
glycolytic enzymes Hk1, Hk2, and Pfkl, as well
as Ldha, the enzyme responsible for converting
pyruvate to lactate (Figures 4A and S4A). These
data suggest that KrasG12D is essential for
glucose utilization in this model through the
regulation of multiple rate-limiting steps
including those that govern glucose uptake
and subsequent metabolism. Interestingly, we
also observed that KrasG12D inactivation wasnot accompanied by significant alterations to TCA cycle interme-
diates (Figure S4B). This finding is in line with a model whereby
proliferating cells divert glucose metabolites into anabolic
processes (e.g., nucleotide and lipid biosynthesis) whereas
alternative carbon sources are utilized to fuel the TCA cycle
(Vander Heiden et al., 2009). Indeed, consistent with previous
reports (Gao et al., 2009; Wise et al., 2008), glutamine is the
major carbon source for the TCA cycle in the KrasG12D-driven
PDAC cells as shown by uniformly labeled (U-13C6)-glucose
and U-13C5-glutamine tracing (Figure S4C).
KrasG12D Activates the Hexosamine Biosynthesis
Pathway and Protein Glycosylation
Because KrasG12D-regulated glucose metabolites, including
G6P and F6P, are precursors for other glucose-utilizing path-
ways, namely the hexosamine biosynthesis pathway (HBP) and
pentose phosphate pathway (PPP), we audited these pathways
immediately following KrasG12D inactivation. Steady-state
metabolite profiling showed a significant decrease in glucos-
amine-6-phosphate (GlcN-6P), the product of the committed
step governing entry into HBP (Figures 5A and 5B). Correspond-
ingly, downregulation of the rate-limiting enzyme, Gfpt1, was
documented at the transcriptional and protein levels (Figures
5C and 5D). Moreover, the GSEA showed downregulation of
O-glycosylation and glycan structure biosynthesis pathways
(Figures 3B and S5A) and western blotting of cells off doxy
showed a decrease in the levels of total O-linked N-acetylglu-
cosamine (O-GlcNAc) posttranslational modification (Figure 5E),, 656–670, April 27, 2012 ª2012 Elsevier Inc. 659
Figure 3. Transcriptional Changes Induced by KrasG12D Inactivation
(A)Orthotopic xenograft tumorswere generated fromfive independent primary iKras p53L/+PDACcell lines. Animalswere kept on doxy for 2weeks until tumorswere
fullyestablished.Halfof theanimalswerepulledoff doxy for24hratwhichpoint tumor lysatewasprepared.RasactivitywasmeasuredwithRaf-RBDpull-downassay.
660 Cell 149, 656–670, April 27, 2012 ª2012 Elsevier Inc.
data supported by the fact that the HBP provides the substrate
for O- and N-linked glycosylation. This profile of reduced glyco-
sylation is comparable to that observed upon glucose starvation
(Figure 5E) and strongly indicates that oncogenic KrasG12D is
essential for the maintenance of protein glycosylation in estab-
lished tumors.
To further substantiate the essentiality of KrasG12D-mediated
control of protein glycosylation, we assessed the impact of
shRNA knockdown of Gfpt1. Consistent with its pivotal role in
providing protein glycosylation substrates, Gfpt1 knockdown
reduced the overall O-linked glycosylation to a level similar to
that of tumor cells in which KrasG12D is extinguished (Figure 5F).
Gfpt1 knockdown also inhibited the clonogenic and soft-agar
growth of tumor cells from both the iKras p53L/+ and the
LSL-KrasG12D p53L/+ tumor cells (Figures 5G and 5H) and sup-
pressed xenograft tumor growth in vivo (Figure 5I). Notably,
tumors that emerged in the Gfpt1 knockdown group showed
recovery of Gfpt1 expression (Figure S5B). Thus, KrasG12D-medi-
ated tumor maintenance is at least partially dependent upon its
stimulation of the HBP and associated protein glycosylation.
KrasG12D Promotes Ribose Biogenesis through
the Nonoxidative Arm of the PPP
The PPP utilizes glucose to generate the ribose ring of DNA/RNA
and to maintain cellular reducing power in the form of NADPH
(Deberardinis et al., 2008b). Metabolomic profiling also revealed
significant changes in several metabolites from the PPP (Fig-
ure 6A). In particular, an intermediate unique to the PPP, sedohe-
pulose-7-phosphate (S7P), was significantly reduced upon
KrasG12D extinction (Figure 6C). To further elucidate the effect
of KrasG12D activity on glucose catabolism through the PPP,
we used U-13C6-glucose to trace glucose flux into the PPP.
Consistent with the steady-state data, we observed that
KrasG12D enhanced glycolytic flux without affecting the flux of
glycolytic metabolites into the TCA cycle (Figure S6A and data
not shown). Moreover, we observed a dramatic reduction in
flux of U-13C6-glucose into ribose-5-phosphate (R5P), S7P,
and erythose-4-phosphate (E4P), components that are unique
to the nonoxidative arm of the PPP (Figure 6B). This was espe-
cially striking given that we did not observe changes in flux
through the oxidative arm of the PPP (Figure 6B), nor were sig-
nificant changes evident by steady-state profiling (Figure 6C).
Given the link between oncogenic Kras signaling and the non-
oxidative arm of the PPP, we sought to compare and quantify
flux through the two arms (oxidative and nonoxidative) of
the PPP.
It has been suggested that the oxidative and nonoxidative
arms of the PPP can be decoupled to facilitate ribose biosyn-
thesis without affecting the cellular redox balance (NADP+/
NADPH ratio) (Boros et al., 1998). To explore this possibility in
the context of KrasG12D-driven PDAC, 14C1- or
14C6-labeled(B) Heat maps of the genes enriched in indicatedmetabolism pathways illustrate th
are representative of log2 values of each replicate from either xenograft tumors or
mean expression level within the group and green signal denotes lower express
(C) GSEA plot of steroid biosynthesis (top), pyrimidine metabolism (middle), and O
gene expression profiles. NES denotes normalized enrichment score.
See also Figure S3.glucose was used to measure the production of CO2 from the
oxidative PPP (14C1-CO2) relative to that generated from the
glycolysis-TCA cycle route (14C6-CO2). Consistent with our
previous data showing that KrasG12D deinduction exerts
a minimal effect on TCA cycle intermediates (Figure S4B), no
obvious change in the release of 14C6-CO2 was observed upon
doxy withdrawal (Figure S6B). More importantly, no significant
decrease in the release of 14C1-CO2 was detected (Figure S6B),
indicating that KrasG12D extinction was not associated with
decreased flux through the oxidative arm of the PPP. In addition,
cellular reduced glutathione (GSH) and oxidized glutathione
(GSSG) levels, which are regulated by NADPH, were not signifi-
cantly altered byKrasG12D inactivation, asmeasured by bothme-
tabolomic profiling and biochemical analysis (Figures 6C and
S6C). These results provide strong evidence that KrasG12D
does not mediate the oxidative arm of the PPP.
To further interrogate the differential abundance of nonoxida-
tive PPP metabolites in an oncogenic Kras-dependent manner,
we traced the incorporation of individual glucose carbons using
1,2-labeled 13C-glucose. As shown in Figure S6D, KrasG12D
extinction leads to a significant decrease in 1,2-13C-labeled
G3P and F6P (glycolytic and PPPmetabolites) and the nonoxida-
tive PPP-specific metabolites S7P and sedoheptulose 1,7-
bisphosphate (SBP). Consistent with the 1,2-labeling experi-
ment, we also observed a significant decrease of SBP upon
KrasG12D inactivation in the steady-state analysis (Figure 6C).
SBP was recently shown to be a metabolite in the nonoxidative
PPP, whose hydrolysis to S7P provides the thermodynamic
driving force to propel ribose biogenesis without engaging the
oxidative arm (Clasquin et al., 2011). The downregulation of
SBP upon oncogene extinction implies that KrasG12D may utilize
this mechanism to facilitate flux through the nonoxidative arm of
the PPP, although the enzyme responsible for mediating this
reaction in mammals remains to be discovered.
A primary role of the nonoxidative arm of the PPP is to
generate ribose-5-phosphate (R5P). As such, we hypothesized
that the flux of glucose into the nonoxidative arm of the PPP
by KrasG12D occurs to provide tumor cells with sufficient R5P
for DNA/RNA biosynthesis. To explore this possibility, we used
14C1- or
14C6-labeled glucose to track the contribution of oxida-
tive versus nonoxidative PPP into DNA and RNA. Whereas
14C6-labeled glucose will give rise to radioactive DNA/RNA
whether it is used by the oxidative or the nonoxidative arm of
the PPP, 14C1-labeled glucose will only give rise to radioactive
DNA/RNA if it is used by the nonoxidative arm (the 14C1 label is
lost as CO2 through the oxidative arm; Figure S6B). As shown
in Figure 6E, KrasG12D extinction leads to dramatic drop in the
incorporation of both 14C1- and
14C6-labeled glucose into
DNA/RNA, clearly demonstrating a predominant and KrasG12D-
mediated role for the nonoxidative arm of the PPP in R5P-
biogenesis. These data reveal an important role for KrasG12D ine changes in gene expression upon doxy withdrawal. Expression levels shown
cultured parental cell lines. Red signal denotes higher expression relative to the
ion relative to the mean expression level within the group.
-glycan biosynthesis (bottom) pathways based on the off-doxy versus on-doxy
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preferential maintenance of glycolytic flux through the nonoxida-
tive arm of the PPP in PDAC tumors.
Inhibition of the Nonoxidative PPP Suppresses
KrasG12D-Dependent Tumorigenesis
In agreement with the specific regulation of the nonoxidative arm
of the PPP, the enzymes involved in the oxidative arm, including
G6pd, Pgls, and Pgd, as well as the enzymatic activity of G6pd
(the rate-limiting step for the oxidative arm) were not altered
upon KrasG12D extinction (Figures 6D and S6E). In contrast, the
expression levels ofRpia andRpe, enzymes that regulate carbon
exchange reactions in the nonoxidative arm of the PPP, were
significantly decreased (Figure 6D). In agreement with their roles
in the nonoxidative PPP, knockdown of either Rpia or Rpe, or the
combination, significantly reduced the flux of 14C1-labeled
glucose into DNA/RNA (Figures 6F and S6F), indicating that
the selective regulation of nonoxidative PPP flux by oncogenic
Kras is, at least, partially mediated through Rpia and Rpe.
More importantly, although Rpia or Rpe knockdown moderately
suppresses the clonogenic activity of iKras p53L/+ tumor cells in
high-glucose (11 mM), the inhibitory effect is dramatically
enhanced when cells were switched to low-glucose containing
media (1 mM) (Figures 6G and 6H), a condition that may reflect
the decreased glucose uptake and glycolytic flux after KrasG12D
extinction. These findings were corroborated with the decrease
in xenograft tumor growth upon Rpia or Rpe knockdown (Fig-
ure 6I), further supporting the functional importance of the non-
oxidative PPP during KrasG12D-mediated PDAC maintenance.
KrasG12D Reprograms Metabolism in PDAC through
MAPK and Myc Pathways
To further dissect the downstream mechanism of KrasG12D-
mediated metabolic reprogramming, we used specific pharma-
cological inhibitors to examine the impact of effector pathways
on tumor metabolism. As shown in Figure 7A, the expression
of several glycolytic genes (Glut1, Hk1, Eno1, Ldha), the rate-
limiting HBP gene (Gfpt1), as well as a nonoxidative PPP gene
(Rpia) are significantly decreased by MEK inhibition (AZD8330)
at a dose that exerts a similar effect on ERK phosphorylation
as that observed upon doxy withdrawal (Figure S7A). Consis-
tently, MAPK inhibition recapitulated the KrasG12D inactivation-
induced metabolite changes in the glycolysis, HBP and nonoxi-
dative PPP pathways (Figure S7B). These data indicate that theFigure 4. KrasG12D Extinction Leads to Decreased Glucose Uptake and
(A) Summary of the changes in glycolysis upon KrasG12D inactivation. Metabolit
graphs indicate the relative expression levels of differentially expressed glycolytic
names for those enzymes that exhibited significant changes are also highlighted i
significant are illustrated in gray.
(B) Heat map of those metabolites that are significantly and consistently change
targeted LC-MS/MS using SRM. Cells were maintained in the presence or abs
triplicates for each treatment condition. The averaged ratios of off-doxy over on-
map. Asterisks indicate metabolites involved in glucose metabolism that decrea
(C and D) iKras p53L/+ cells were maintained in the presence or absence of doxy fo
measured and normalized to cell numbers.
(E) Fold changes of glycolytic intermediates upon doxy withdrawal for 24 hr.
bisphosphoglycerate; B(2,3)PG, 2,3-bisphosphoglycerate; DHAP, dihydroxyacet
G6P, glucose 6-phosphate; G3P, glyceraldehyde 3-phosphate; PEP, phosphoen
See also Figure S4.MAPK pathway is a major effector of oncogenic Kras-mediated
glucose metabolism remodeling in PDAC, which is consistent
with the rapid decrease of MAPK signaling upon oncogene inac-
tivation (Figures 2B, S2C, and S2D). In contrast, although mTOR
signaling is also suppressed upon KrasG12D inactivation, Rapa-
mycin treatment did not induce extensive changes in glucose
metabolism. In agreement with the minimal alteration in Akt
signaling upon oncogene silencing (Figures S2C and S2D), inhi-
bition of PI3K-AKT signaling (BKM120) did not exhibit a signifi-
cant impact on iKras-directed tumor metabolism (Figures 7A,
S7A, and S7B).
To gain further insight into the KrasG12D-mediated transcrip-
tional regulation that facilitates metabolic reprogramming,
promoter analysis was performed on differentially expressed
genes upon KrasG12D inactivation. In silico cis-element analysis
revealed a highly significant enrichment of the Myc binding
element (Figure S7C, p = 5.11 3 1065). Furthermore, Myc
protein level was decreased upon KrasG12D inactivation or
MEK inhibitor treatment (Figures S7A and S7D). Because it has
been shown thatMyc is required for Ras-dependent tumormain-
tenance (Soucek et al., 2008), we hypothesized that Myc may be
a prominent mediator of the KrasG12D-dependent transcriptional
regulation of metabolism genes. Indeed, shRNA knockdown of
Myc in iKras PDAC cells significantly downregulated the expres-
sion of metabolism genes in the glycolysis, HBP, and nonoxida-
tive PPP pathways (Figures S7E and S7F). Another possible
candidate mediator of Kras-induced transcriptional changes of
metabolism genes was HIF1a. Although there was some enrich-
ment of HIF1a promoter elements in the Kras transcriptional
changes, knockdown of HIF1a had only minimal impact on
metabolic enzyme expression (data not shown). Together, our
data indicates that the MAPK pathway and Myc-directed tran-
scriptional control play key roles for KrasG12D-mediated meta-
bolic reprogramming in PDAC.
DISCUSSION
In this study, an inducible KrasG12D-driven PDAC model
provided genetic evidence that oncogenic Kras serves a tumor
maintenance role in fully established PDAC. Integrated genomic,
biochemical, and metabolomic analyses immediately following
KrasG12D extinction revealed a prominent perturbation of
multiple metabolic pathways. In particular, KrasG12D exertsGlycolysis
es that decrease upon doxy withdrawal are indicated with green arrows. Bar
enzymes that showed a significant decrease in the absence of doxy; the gene
n the cartoon in blue. Glycolytic enzymes whose change in expression was not
d upon doxy withdrawal between the two iKras p53L/+ lines as determined by
ence of doxy for 24 hr, at which point metabolite levels were measured from
doxy levels for differentially regulated metabolites are represented in the heat
se upon doxy withdrawal.
r 24 hr. Relative changes of glucose (C) or lactate (D) levels in the mediumwere
*p < 0.05; **p < 0.01. Error bars represent SD of the mean. B(1,3)PG, 1,3-
one phosphate; FBP, fructose 1,6-bisphosphate; F6P, fructose 6-phosphate;
olpyruvate; 3PG, 3-phosphoglycerate.
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Figure 5. KrasG12D Inactivation Leads to Inhibition of the Hexosamine Biosynthesis Pathway and Protein O-Glycosylation
(A) Summary of changes in the HBP upon KrasG12D inactivation. Metabolites that decrease upon doxy withdrawal are indicated with green arrows. Differentially
expressed genes upon doxy withdrawal are highlighted in blue.
(B) Fold change of metabolites in the HBP upon doxy withdrawal for 24 hr.
(C and D) Relative mRNA (C) and protein levels (D) of Gfpt1 in the presence or absence of doxy for 24 hr.
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potent control of glycolysis through regulation of glucose trans-
porter and several rate-limiting enzymes at the transcriptional
level, which collectively serve to shunt glucose metabolism
toward anabolic pathways, such as HBP for protein glycosyla-
tion and PPP for ribose production (Figure 7B). Notably, we iden-
tified an unexpected connection between oncogenic Kras and
the nonoxidative arm of the PPP, which functions to provide
precursors for DNA and RNA biosynthesis. The functional valida-
tion of several KrasG12D-regulated metabolic enzymes provide
candidate therapeutic targets and associated biomarkers for
the signature oncogene in this intractable disease.
KrasG12D Is Required for PDAC Maintenance
Studies in multiple GEMMs have shown that tumor maintenance
is often dependent on the driver oncogene that initiates tumor
development (Chin et al., 1999; Felsher and Bishop, 1999; Fisher
et al., 2001; Moody et al., 2002). However, recent in vitro studies
in human PDAC cell lines have indicated that certain pancreatic
cell lines expressing mutant Kras may lose dependence on this
oncogene (Singh et al., 2009), raising the question whether onco-
genic Kras remains relevant to tumor maintenance in advanced
PDAC in the in vivo setting. In our study, the observation of
a complete regression of fully established tumors 1 week
upon KrasG12D extinction underscores the essential role of this
signature oncogene in PDAC, although we cannot exclude the
possibility that residual cancer cells may remain. Additionally,
our data uncovers a key relationship between the oncogenic
Kras-expressing tumor cells and the prominent desmoplastic
stroma that is characteristic of PDAC. Upon Kras extinction,
there is a rapid reduction in SMA-positive pancreatic stellate
cells. Recent work has shown a correlation between stromal
SMA positivity and poor prognosis in PDAC patients (Fujita
et al., 2010). It is tempting to speculate that KrasG12D may
promote the paracrine secretion of prostromal factors such as
Sonic Hedgehog (Neesse et al., 2011); however, further work
will be necessary to define this complex relationship.
Oncogenic KrasG12D Directs Glucose Metabolism
into Biosynthetic Pathways in PDAC
The reprogramming of cellular metabolism to support contin-
uous proliferation is a hallmark of cancer (Hanahan and Wein-
berg, 2011). Our analysis in vivo following KrasG12D extinction
showed rapid downregulation of specific metabolic enzymes
and their pathways prior to any discernible biological impact
(e.g., morphological or proliferative changes), a finding consis-
tent with the active control of tumor cell metabolism by KrasG12D.
Indeed, the Kras oncogene is known to induce aerobic glycolysis
(Racker et al., 1985), and PDAC cells have been shown previ-(E) Western blot analysis for O-linked N-acetylglucosamine (O-GlcNAc) levels i
samples, MEFs were cultured in the presence or absence of glucose for 24 hr.
(F) Western blot analysis for O-GlcNAc and Gfpt1 levels in cells infected with shR
(G and H) Clonogenic assay (G) and soft-agar colony formation assay (H) for iKr
Gfpt1.
(I) iKras p53L/+ cell lines were infected with shRNA against GFP or Gfpt1 and sub
shown are representative of results from three independent cell lines. *p < 0.05;
Error bars represent SD of the mean. GlcNAc-1P, N-acetylglucosamine 1-phos
6-phosphate; UDP-GlcNAc, UDP-N-acetylglucosamine. See also Figure S5.ously to have metabolism consistent with elevated aerobic
glycolysis (Zhou et al., 2011). Interestingly, this metabolic switch
may be dependent on cell type or oncogenic Ras isoform as H-
Ras transformed mesenchymal stem cells do not depend on
increased glycolysis for ATP production during transformation
(Funes et al., 2007).
The striking and specific transcriptional alteration of metabolic
gene expression, which shows high concordance with the actual
changes in metabolism, adds to the well-established means
of metabolic regulation by allosteric effects on rate-limiting
enzymes. Our findings underscore the relevance of gene expres-
sion as a mechanism to achieve metabolic reprogramming in
tumor cells to determine themetabolic flux route and rate (DeBer-
ardinis et al., 2008a). Another important feature of such transcrip-
tional regulation is that the rewiring of metabolism pathways by
the Kras oncogene is achieved through the highly coordinated
control over multiple nodes, including rate-limiting enzymes.
Our work establishes that KrasG12D extinction leads to inhibi-
tion of glucose uptake and a decrease in several glycolytic inter-
mediates, including G6P, F6P, and FBP. Although aerobic
glycolysis is recognized as inefficient from a bioenergetics
perspective, metabolic reprogramming to a glycolytic state has
been proposed as a mechanism which allows the allocation of
glycolytic intermediates into biosynthetic pathways (Vander Hei-
den et al., 2009). Indeed, we have demonstrated the enhanced
glycolytic flux is diverted into the nonoxidative PPP to facilitate
ribose biogenesis. Furthermore, such hypotheses are also sup-
ported by the observation that amplification/overexpression of
PHGDH, a rate-limiting enzyme functioning to divert 3-phospho-
glycerate (a glycolytic intermediate) into the serine biosynthesis
pathway, facilitates tumor growth in certain contexts (Locasale
et al., 2011; Possemato et al., 2011).
The Activation of Hexosamine Biosynthesis
and Glycosylation Pathways by KrasG12D
In this study, we provide evidence that oncogenic Kras plays
a prominent role in the flux of glucose into the HBP. Our data
shows that the expression of Gfpt1, the first and rate-limiting
step of HBP, is strongly downregulated upon KrasG12D inactiva-
tion. The HBP is obligatory for various glycosylation processes,
such as protein N- or O-glycosylation and glycolipid synthesis.
Although its function during tumorigenesis is poorly understood,
recent studies indicate that the HBP is important for the coordi-
nation of nutrient uptake, partially through modulating the glyco-
sylation and membrane localization of growth factor receptors
(Wellen et al., 2010). Protein and lipid glycosylation is an abun-
dant posttranslational modification and plays fundamental regu-
latory roles in tumor cell proliferation, invasion/metastasis,n cells maintained in the presence or absence of doxy for 24 hr. For control
NA against GFP or Gfpt1.
as p53L/+ or LSL-Kras p53L/+ PDAC cells infected with shRNA against GFP or
cutaneously injected into nude mice. Tumor volumes were measured and data
**p < 0.01.
phate; GlcNAc-6P, N-acetylglucosamine 6-phosphate; GlcN6P, glucosamine
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Figure 6. KrasG12D Preferentially Enhances Nonoxidative PPP to Support Ribose Biogenesis
(A) Summary of changes in the PPP upon KrasG12D inactivation. Metabolites that decrease upon doxy withdrawal are indicated with green arrows. Differentially
expressed genes upon doxy withdrawal are highlighted in blue.
(B) iKras p53L/+ cells were maintained in the presence or absence of doxy for 24 hr, at which point U-13C glucose labeling kinetics for the indicated metabolites
were compared at 1, 3, and 10 min.
(C) Fold changes for metabolites in the PPP upon doxy withdrawal for 24 hr.
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Figure 7. MAPK Pathway Is Critical for KrasG12D-
Mediated Metabolism Reprogramming
(A) iKras p53L/+ cells were treated with AZD8330 (50 nM),
BKM120 (150 nM), or Rapamycin (20 nM) for 18 hr. In
parallel, cells were cultured in the presence or absence of
doxy for 24 hr to serve as controls and relative mRNA
levels of indicated metabolism genes were measured by
QPCR. Error bars represent SD of the mean. *p < 0.05;
**p < 0.01.
(B) Schematic representation of the shift in glucose
metabolism upon KrasG12D withdrawal. Activation of
oncogenic Kras enables PDAC tumor maintenance
through the increased uptake of glucose and subsequent
shunting into glycolysis, the HBP pathway (to enable
enhanced glycosylation) and the nonoxidative arm of the
PPP (to facilitate ribose biosynthesis for DNA/RNA).
Glucose flux into the oxidative arm of the PPP and the TCA
cycle do not change when KrasG12D is inactivated.angiogenesis, and immune evasion (Fuster and Esko, 2005; Hart
and Copeland, 2010). Ras oncogenes have been shown to
induce N-glycosylation and Kras mutation in human colorectal
cancer cells is associated with increased N-linked carbohydrate
branching (Bolscher et al., 1988; Dennis et al., 1989; Rak et al.,
1991; Wojciechowicz et al., 1995). Here, we provided additional
evidence that oncogenic Kras signaling also sustains protein
O-glycosylation during tumor maintenance.
KrasG12D Induces Nonoxidative PPP Flux
The PPP is considered important for tumorigenesis as it provides
NADPH for macromolecule biosynthesis and ROS detoxifica-
tion, as well as ribose 5-phosphate for DNA/RNA synthesis
(Boros et al., 1998; Deberardinis et al., 2008b). Additionally, it
has been shown that the Ras oncogene promotes resistance
to oxidative stress through GSH-based ROS scavenger path-
ways (DeNicola et al., 2011; Recktenwald et al., 2008), and this
is likely mediated in part by the production of NADPH through
the oxidative arm of the PPP. In fact, the oxidative arm of the
PPP has been shown to be activated by Kras oncogene-medi-(D) Relative mRNA levels of PPP genes in the presence or absence of doxy for 24 hr.
(E) iKras p53L/+ cells were maintained in the presence or absence of doxy for 24 hr, followed by a 24
radioactivity into DNA or RNA were determined and normalized to DNA or RNA concentration.
(F) iKras p53L/+ cells were infected with shRNA against Rpia and Rpe individually or in combination. shR
with 1-14C glucose and incorporation of radioactivity into DNA and RNA was determined as in (E).
(G) iKras p53L/+ cells were maintained under high (11 mM) or low (1 mM) glucose, and clonogenic act
GFP, Rpia, or Rpe.
(H) Quantification of colony numbers.
(I) iKras p53L/+ cells were infected with shRNA against GFP, Rpia, or Rpe and subcutaneously injected
shown are representative of results from three independent cell lines.
Error bars represent SD of the mean. *p < 0.05; **p < 0.01. E4P, erythrose 4-phosphate; GdL6P, 6-phos
oxidized glutathione; 6PG, 6-phosphogluconate; R5P, ribose 5-phosphate; Ru5P, ribulose 5-phosph
5-phosphate. See also Figure S6.
Cell 149ated transformation to promote cell proliferation
(Vizan et al., 2005; Weinberg et al., 2010).
Notably, we did not observe obvious changes
in the oxidative PPP but rather a role for onco-
genic Kras signaling in the preferential mainte-
nance of the nonoxidative arm of PPP. It hasbeen recently shown that p53 inhibits G6PD activity through
direct binding (Jiang et al., 2011). Therefore, it is possible that
the oxidative PPP is largely regulated by p53 deficiency in
PDAC tumor cells, whereas oncogenic signaling from KrasG12D
sustains the nucleotide pool through de novo biosynthetic path-
ways. Indeed, recent evidence suggests that the nonoxidative
PPP is preferentially upregulated in tumor cells including pancre-
atic cancer (Boros et al., 2005; Tong et al., 2009). Our data indi-
cate that such metabolic changes are tightly regulated by onco-
genic Kras and that suppression of the nonoxidative PPP blocks
tumorigenic activity. These data suggest that inhibition of early
steps of nucleotide biosynthesis, such as R5P production, could
provide a useful therapeutic strategy for KrasG12D mutant
tumors.
One interesting observation of KrasG12D-mediated metabolic
reprogramming is the decrease in SBP upon KrasG12D inactiva-
tion. Interestingly, an enzyme was recently discovered in yeast
that dephosphorylates SBP thereby providing the thermody-
namic driving force for canonical F-type nonoxidative PPP flux
independent of the oxidative arm (Clasquin et al., 2011).hr labeling with 1-14C or 6-14C glucose. Incorporation of
NA against GFPwas used as a control. Cells were labeled
ivity was determined for cells infected with shRNA against
into nude mice. Tumor volumes were measured and data
phoglucono-d-lactone; GSH, reduced glutathione; GSSG,
ate; SBP, sedoheptulose 1,7-bisphosphate; X5P, xylulose
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However, attempts at identifying a mammalian ortholog have
been unsuccessful. Alternatively, SBP has also been reported
to function in an alternative ‘‘L-type’’ PPP in liver that eventually
feeds into the nonoxidative arm (Williams et al., 1987). Our
finding provides a unique connection of this pathway to a driver
oncogene and may provide a novel diagnostic and therapeutic
avenue for these Ras-driven tumors.EXPERIMENTAL PROCEDURES
Generation of Plasmid Construct and Transgenic Mice
A fragment containing mutant murine KrasG12D cDNA (Johnson et al., 2001)
was used to generate the tetO_Lox-Stop-Lox-KrasG12D transgene by standard
cloning methods. The detailed method and additional alleles are described in
Extended Experimental Procedures. All manipulations were performed under
IACUC approval protocol number 04116.
Xenograft Studies
For orthotopic xenografts, 5 3 105 cells suspended in 10 ml 50% Matrigel (BD
Biosciences)/Hanks buffered saline solution were injected pancreatically into
NCr nude mice (Taconic). Animals were fed with doxy water.
For Sub-Q xenografts, 1 3 106 cells suspended in 100 ml Hanks buffered
saline solution were injected subcutaneously into the lower flank of NCr
nude mice (Taconic). Animals were fed with doxy water. Tumor volumes
were measured every 3 days starting from Day 4 postinjection and calculated
using the formula, volume = length3width2/2. All xenograft experiments were
approved under IACUC protocol 04114.
Immunohistochemistry and Western Blot Analysis
Tissueswere fixed in 10% formalin overnight and embedded in paraffin. Immu-
nohistochemical analysis was performed as described (Aguirre et al., 2003).
The primary antibodies used for immunohistochemistry or western are listed
in Extended Experimental Procedures.
Targeted Mass Spectrometry
The preparation and measurement of metabolites by LC-MS/MS are
described in Extended Experimental Procedures.
Isotope Labeling and Kinetic Profiling
Glucose- or glutamine-free RPMI was supplementedwith 10%dialyzed serum
and 1,2-13C2-glucose, U-
13C6-glucose, or U-
13C5-glutamine (Cambridge
Isotope Labs) to 11 mM (for glucose) or 2 mM (for glutamine). Cells were main-
tained in the presence or absence of doxy for 24 hr, at which point labeled
media was added to biological triplicates. For glucose-flux analysis, cells
were maintained in the presence or absence of doxy for 24 hr and then media
was replaced with that containing U-13C6-glucose.
1-14C/6-14C Glucose Incorporation into Nucleotides
Cells were maintained in the presence or absence of doxy for 24 hr, at which
point biological triplicates were treatedwith 1 mCi 1-14C or 6-14C glucose. Cells
were harvested 24 hr later. DNA or RNA were isolated with QIAGEN kits ac-
cording to the manufacturer’s instructions and quantified using a NanoDrop
instrument. Equal volumes of DNA/RNA were added to scintillation vials and
radioactivity was measured by liquid scintillation counting and normalized to
the DNA/RNA concentration.
14C Glucose Incorporation into CO2
Cells were maintained in the presence or absence of doxy for 24 hr, at which
point biological triplicates were treated with 1 mCi 1-14C or 6-14C glucose and
incubated at 37C for the indicated time points. To release 14CO2, 150 ml of 3M
perchloric acid was added to each well and immediately covered with phenyl-
ethylamine saturated Whatman paper and incubated at room temperature
overnight. The Whatman paper was then analyzed by scintillation counting.668 Cell 149, 656–670, April 27, 2012 ª2012 Elsevier Inc.Metabolite Analysis of Spent Medium
Cells were seeded in 12-well plates in triplicate for 24 hr followed by culture in
doxy-free medium or medium containing doxy for additional 24 hr. Glucose
and lactate concentrations were measured in fresh and spent medium using
a Yellow Springs Instruments (YSI) 7100. Glucose data are presented as net
decrease in concentration, and lactate as net increase in concentration after
normalization to cell numbers.
Expression Profiling and Bioinformatics Analysis
mRNA expression profiling and data analysis are described in Extended
Experimental Procedures.
Lentiviral-Mediated shRNA Targeting
Lentiviral shRNA clones targeting Gfpt1, Rpia, Rpe, and nontargeting control
construct shGFP were obtained from the RNAi Consortium at the Dana-
Farber/Broad Institute. The clone IDs for the shRNA are listed in Extended
Experimental Procedures.
Statistical Analysis
Tumor-free survivals were analyzed using GraphPad Prism4. Statistical anal-
yses were performed using nonparametric Mann-Whitney test. Other compar-
isons were performed using the unpaired Student’s t test. For all experiments
with error bars, standard deviation (SD) was calculated to indicate the variation
within each experiment and data, and values represent mean ± SD.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at doi:10.1016/
j.cell.2012.01.058.
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